510(k) Summary: DSU Dual Stage Ultrafilter

Nephros Inc.
41 Grand Ave
River Edge, NJ 07661
Establishment Registration # 3003337893
Vikki M. O'Connor, Director QA/RA
41 Grand Ave
River Edge, NJ 07661
201-207-2490 (p)
201-343-520 7 (f)
vhoffman@nephros.com
March 30, 2009
DSU Dual Stage Ultrafilter
Class II
21 CFR Part 876.5665 Water Purification System for
Hemodialysis
FIP
FiberFlo™ Hollow Fiber Cartridge Water Filters – K983126
The DSU Dual Stage Ultrafilter is a hollow fiber filter that
removes bacteria, viruses, endotoxin and particulate from
water and bicarbonate concentrate used in hemodialysis.
The DSU Dual Stage Ultrafilter is intended to be used to
filter water or bicarbonate concentrate used in
hemodialysis devices. The DSU assists in providing
hemodialysis quality water or bicarbonate concentrate. The
device is not a complete water treatment system, but
serves to remove biological contaminants. Therefore it
must be used in conjunction with other water treatment
equipment (i.e., RO, DI, etc.).

,	
Summary of the	The proposed device has the same technological
Technological	characteristics and is similar in design as compared to the
Characteristics	predicate device.
Assessment of	The DSU Dual Stage Ultra Filter has been tested for
Non-clinical	performance. The tests conducted include Flow Rate
Performance Data /	versus Pressure Drop, Bicarbonate Composition Effect,
Substantial	Pyrogen Removal, Virus Challenge Test, Bacteria
Equivalence	Challenge Test and Chemical Compatibility. This filter was
	found to be substantially equivalent to the predicate
	Minntech Fiberflo Filter (K983126).
i .	

JUN 29 2009

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Vikki M. O'Connor Director, QA/RA Nephros, Inc. 41 Grand Avenue RIVER EDGE NJ 07661

Re: K090885

Trade/Device Name: Nephros Inc. DSU Filter Regulation Number: 21 CFR §876.5665

Regulation Name: Water purification system for hemodialysis

Regulatory Class: II Product Code: FIP Dated: March 30, 2009

Received: April 3, 2009

Dear Ms. O'Connor:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Janine M. Morris

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Nephros Inc. DSU Dual Stage Ultrafilter

Indications for Use

510(k) Number (if known): K_090885 Device Name: Nephros Inc. DSU Filter	
Indications For Use:	
The DSU Dual Stage Ultrafilter is intended to be used in hemodialysis devices. The DSU Ultrafilter or bicarbonate concentrate. The device is not a cremove biological contaminants. Therefore, it must treatment equipment (i.e., RO, DI, etc.).	r assists in providing hemodialysis quality water omplete water treatment system, but serves to
Prescription UseX AND/OR (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE Concurrence of CDRH, Office of Device	-CONTINUE ON ANOTHER PAGE IF NEEDED)Evaluation (ODE)

(Division Sign-Off)
Division of Reproductive, Abdominal, and Radiological Devices

510(k) Number

Page 1 of 1